- Home
- ANAB vs REX Comparison
ANAB vs REX Comparison
Compare ANAB & REX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- REX
- Stock Information
- Founded
- ANAB 2005
- REX 1980
- Country
- ANAB United States
- REX United States
- Employees
- ANAB N/A
- REX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- REX Major Chemicals
- Sector
- ANAB Health Care
- REX Industrials
- Exchange
- ANAB Nasdaq
- REX Nasdaq
- Market Cap
- ANAB 621.1M
- REX 699.5M
- IPO Year
- ANAB 2017
- REX N/A
- Fundamental
- Price
- ANAB $23.41
- REX $52.76
- Analyst Decision
- ANAB Buy
- REX Strong Buy
- Analyst Count
- ANAB 10
- REX 1
- Target Price
- ANAB $44.25
- REX $50.00
- AVG Volume (30 Days)
- ANAB 566.9K
- REX 135.8K
- Earning Date
- ANAB 08-04-2025
- REX 08-26-2025
- Dividend Yield
- ANAB N/A
- REX N/A
- EPS Growth
- ANAB N/A
- REX N/A
- EPS
- ANAB N/A
- REX 3.24
- Revenue
- ANAB $111,872,000.00
- REX $639,600,000.00
- Revenue This Year
- ANAB N/A
- REX $3.27
- Revenue Next Year
- ANAB $24.39
- REX $17.11
- P/E Ratio
- ANAB N/A
- REX $16.30
- Revenue Growth
- ANAB 387.20
- REX N/A
- 52 Week Low
- ANAB $12.21
- REX $33.45
- 52 Week High
- ANAB $41.31
- REX $52.70
- Technical
- Relative Strength Index (RSI)
- ANAB 57.46
- REX 75.75
- Support Level
- ANAB $21.87
- REX $48.32
- Resistance Level
- ANAB $24.69
- REX $50.10
- Average True Range (ATR)
- ANAB 1.19
- REX 1.51
- MACD
- ANAB -0.09
- REX 0.15
- Stochastic Oscillator
- ANAB 61.20
- REX 99.21
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.